15
Participants
Start Date
October 9, 2017
Primary Completion Date
March 11, 2022
Study Completion Date
March 11, 2022
Ipilimumab
Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study. On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
Nivolumab
On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
Radiation therapy
Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study.
Weill Cornell Medicine, New York
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Weill Medical College of Cornell University
OTHER